Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Auer J, Eber B  
Current aspects of statins

Journal of Clinical and Basic Cardiology 1999; 2 (2): 203-208

PDF    Summary    Figures   

Fig. 1: Serumcholesterin - KHK-Tod

Keywords: AtheroskleroseCholesterinsenkungHMG-CoA-ReduktasehemmungKoronare HerzkrankheitStatinatherosclerosischolesterol loweringcoronary artery diseaseHMG-CoA-reductase inhibitionStatin

Clinical trials have demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) significantly reduce cardiovascular-related morbidity and mortality in patients with and without coronary artery disease. Furthermore, statins are currently the most potent cholesterol-lowering drugs available. Subanalyses of the LIPID study have shown that patients suffering from unstable angina pectoris had at least the same benefit from statin therapy as did patients after myocardial infarction. Studies recently published (AVERT) or not published yet (MIRACL) provide more information on the topic of therapy with statins in the early phase of acute coronary syndromes. J Clin Basic Cardiol 1999; 2: 203-8.
copyright © 2003–2018 Krause & Pachernegg GmbH | Sitemap | Impressum